Abbisko

Abbisko Therapeutics is a R&D-driven, clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has established a robust in-house R&D engine underpinned by an outstanding discovery team and multi-dimensional discovery platform. With a rich pipeline of 10+ programs focused on oncology — including multiple programs at clinical stage — Abbisko strategically focuses on small molecule precision oncology therapies, small molecule immuno-oncology therapies and combination therapies. The company aspires to become a leading biopharmaceutical company discovering and developing novel, differentiated therapies in cancer and beyond, addressing critical unmet needs for patients in China and globally.